These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8991789)

  • 1. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs.
    So EL; Wolff D; Graves NM; Leppik IE; Cascino GD; Pixton GC; Gustavson LE
    Epilepsy Res; 1995 Nov; 22(3):221-6. PubMed ID: 8991789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy.
    Samara EE; Gustavson LE; El-Shourbagy T; Locke C; Granneman GR; Sommerville KW
    Epilepsia; 1998 Aug; 39(8):868-73. PubMed ID: 9701378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures.
    Gustavson LE; Boellner SW; Granneman GR; Qian JX; Guenther HJ; el-Shourbagy T; Sommerville KW
    Neurology; 1997 Apr; 48(4):1032-7. PubMed ID: 9109895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy.
    Snel S; Jansen JA; Mengel HB; Richens A; Larsen S
    J Clin Pharmacol; 1997 Nov; 37(11):1015-20. PubMed ID: 9505994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of new antiepileptic drugs.
    Gram L
    Epilepsia; 1996; 37 Suppl 6():S12-6. PubMed ID: 8941037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function.
    Lau AH; Gustavson LE; Sperelakis R; Lam NP; El-Shourbagy T; Qian JX; Layden T
    Epilepsia; 1997 Apr; 38(4):445-51. PubMed ID: 9118850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiagabine.
    Schachter SC
    Epilepsia; 1999; 40 Suppl 5():S17-22. PubMed ID: 10530690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical pharmacokinetics of the new antiepileptic drugs.
    Perucca E
    Epilepsia; 1999; 40 Suppl 9():S7-13. PubMed ID: 10612356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy.
    Adkins JC; Noble S
    Drugs; 1998 Mar; 55(3):437-60. PubMed ID: 9530548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin.
    Gustavson LE; Cato A; Boellner SW; Cao GX; Qian JX; Guenther HJ; Sommerville KW
    Am J Ther; 1998 Jan; 5(1):9-16. PubMed ID: 10099032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
    Perucca E; Johannessen SI
    Epileptic Disord; 2003 May; 5 Suppl 1():S17-26. PubMed ID: 12915337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical implications of pharmacology and pharmacokinetics of tiagabine].
    Pita-Calandre E
    Rev Neurol; 1999 Feb 1-15; 28(3):337-9. PubMed ID: 10714305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the antiepileptic drug tiagabine.
    Schachter SC
    Clin Neuropharmacol; 1999; 22(6):312-7. PubMed ID: 10626090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses.
    Gustavson LE; Mengel HB
    Epilepsia; 1995 Jun; 36(6):605-11. PubMed ID: 7555975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine.
    Cato A; Gustavson LE; Qian J; El-Shourbagy T; Kelly EA
    Epilepsia; 1998 Jan; 39(1):43-7. PubMed ID: 9578011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of tiagabine in epileptic patients on monotherapy.
    Ingwersen SH; Pedersen PC; Groes L; Nielsen KK; Aarons L
    Eur J Pharm Sci; 2000 Sep; 11(3):247-54. PubMed ID: 11042231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tiagabine.
    Shinnar S
    Semin Pediatr Neurol; 1997 Mar; 4(1):24-33. PubMed ID: 9097364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled study comparing visual function in patients treated with vigabatrin and tiagabine.
    Krauss GL; Johnson MA; Sheth S; Miller NR
    J Neurol Neurosurg Psychiatry; 2003 Mar; 74(3):339-43. PubMed ID: 12588920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study.
    Peltola J; Peltola M; Auvinen A; Raitanen J; Fallah M; Keränen T
    Acta Neurol Scand; 2009 Jan; 119(1):55-60. PubMed ID: 18616622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.